Influence of 17β-estradiol treatment on the expression of NF-κB in complete hydatidiform mole culture

  • Tatit Nurseta Department of Obstetric and Gynecology, Faculty of Medicine, Universitas Brawijaya, Malang, Indonesia
  • Yahya Irwanto Department of Obstetric and Gynecology, Faculty of Medicine, Universitas Brawijaya, Malang, Indonesia
  • Rahmi Utami Department of Obstetric and Gynecology, Faculty of Medicine, Universitas Brawijaya, Malang, Indonesia
Keywords: 17-β Estradiol, Hydatidiform mole, NF-κB
Abstract viewed: 1140 times
PDF downloaded: 638 times

Abstract

Background: Genetic evidence has established a role of nuclear factor kappa B (NF-κB ) signaling in oncogenesis. However, activity of NF-κB in complete hydatidiform mole (CHM) cell culture under 17β-estradiol (E2) treatment is not yet known. Recently, a positive cross-talk between estrogen receptor (ER) and NF-κB to promote survival and progress of cancer cells to a more aggressive phenotype was established. In the present study, we examined the influence of E2 treatment on the NF-κB expression in CHMâs culture.

Methods: This experimental study measured the expression of NF-κB in CHM culture treated with E2: 10, 100, 300, 600, and 1000 pg/mL and without E2. Imunohistochemistry staining was used to assess the expression of NF-κB. Microphotographs were taken using 400x magnification. Adobe photoshop CS2 was used to assess the NF-κB expression in cell nucleus. The lower the color intensity of cell RGBbv, is the higher the expression of NF-κB in cells. ANOVA test was performed to compare the expression of NF-κB.

Results: NF-κB expression as indicated by color intensity in control group was 114.84 ± 9.02. NF-κB expression in E2 treatment groups were respectively: E2 10 pg/mL: 106.30 ± 13.95; E2 100 pg/mL: 82.47 ± 4.72; E2 300 pg/mL: 82.24 ± 2.67; E2 600 pg/mL: 69.05 ± 6.47; E2 1000 pg/mL: 68.49 ± 2.37. There was progressive decline in color intensity of cells with E2 treatment indicating the increase expression of NF-κB. Significant differences with the control group occurred in doses of E2 100, 300, 600, dan 1000 pg/mL.

Conclusion: Treatment of CHM trophoblast culture with escalating doses of E2 was associated with the increase of NF-κB expression in a dose dependent manner. (Med J Indones. 2013;22:197-201. doi: 10.13181/mji.v22i4.599)

Downloads

Download data is not yet available.

References

  1. Martaadisoebrata D. Pola Epidemiologi Penyakit Trofoblas dalam Kaitannya dengan Prognosis dan Cara Penanggulangannya. Bandung: RSHS/FKUP - Divisi Obstetri Ginekologi; 2002. Indonesian.

  2. Sastradinata I. Problematik Penyakit Trofoblas di Indonesia. Palembang: Universitas Sriwijaya - Divisi Obstetri dan Ginekologi; 2009. Indonesian

  3. Yager JD, Davidson NE. Estrogen carcinogenesis in breast cancer. N Engl J Med. 2006;354(3):270-82. http://dx.doi.org/10.1056/NEJMra050776

  4. Dolcet X, Llobet D, Pallares J, Mathias-Guiu X. NF-κB in development and progression of human Cancer. Virchows Arch. 2005;446(5):475-82. http://dx.doi.org/10.1007/s00428-005-1264-9

  5. Cogswell, P.C, Guttridge, D.C, Funkhouser W, Baldwin Jr A. Selective activation of NF-kappa B subunits in human breast cancer: potential roles for NF-kappa B2/p52 and for Bcl-3. Oncogene. 2000;19(9):1123-31. http://dx.doi.org/10.1038/sj.onc.1203412

  6. Feldman I, Feldman GM, Mobarak C, Dunkelberg JC, Leslie KK. Identification of proteins within the nuclear factor-kappa B transcriptional complex including estrogen receptor-alpha. Am J Obstet Gynecol. 2007;196(4);394.e1-394.e13. http://dx.doi.org/10.1016/j.ajog.2006.12.033

  7. Frasor J, Weaver A, Pradhan M, Dai Y, Miller LD, Lin CY, et al. Positive cross-talk between estrogen receptor and NF-Kappa B in breast cancer. Cancer Res. 2009;69(23):8918-25. http://dx.doi.org/10.1158/0008-5472.CAN-09-2608

  8. Osipo C, Gajdos C, Liu H, Chen B, Jordan VC. Paradoxical action of fulvestrant in estradiol-induced regression of tamoxifen-stimulated breast cancer. J Natl Cancer Inst. 2003;95(21):1597-608. http://dx.doi.org/10.1093/jnci/djg079

  9. King AE, Collins F, Klonisch T, Sallenave JM, Critchley HO, Saunders PT. An additive interaction between the NFkappaB and estrogen receptor signalling pathways in human endometrial epithelial cells. Hum Reprod. 2010;25(2):510-8. http://dx.doi.org/10.1093/humrep/dep421

  10. Nalbandian G, Kovats S. Estrogen, Immunity & Autoimmune Disease. Curr Med Chem–Immun, Endoc & Metab Agents Journal. 2005;5(1):85-91. http://dx.doi.org/10.2174/1568013053005418

  11. Kumar S, Lata K, Mukhopadhyay S, Mukherjee TK. Role of estrogen receptors in pro-oxidative and anti-oxidative actions of estrogens: A perspective. Biochim Biophys Acta. 2010;1800(10):1127-35. http://dx.doi.org/10.1016/j.bbagen.2010.04.011

  12. Stoica GE, Franke TF, Wellstein A, Czubayko F, List HJ, Reiter R, et al. Estradiol rapidly activates Akt via the ErbB2 signaling pathway. Mol Endocrinol. 2007;17(5):818-30. http://dx.doi.org/10.1210/me.2002-0330

Published
2013-12-13
How to Cite
1.
Nurseta T, Irwanto Y, Utami R. Influence of 17β-estradiol treatment on the expression of NF-κB in complete hydatidiform mole culture. Med J Indones [Internet]. 2013Dec.13 [cited 2024Jul.22];22(4):197-01. Available from: http://mji.ui.ac.id/journal/index.php/mji/article/view/599
Section
Basic Medical Research